ImmuneWalk Therapeutics

ImmuneWalk TherapeuticsImmuneWalk TherapeuticsImmuneWalk Therapeutics
  • Home
  • New Biology
  • Our Technology
  • Clinical Program
  • Market Potential
  • News & Events
  • More
    • Home
    • New Biology
    • Our Technology
    • Clinical Program
    • Market Potential
    • News & Events

ImmuneWalk Therapeutics

ImmuneWalk TherapeuticsImmuneWalk TherapeuticsImmuneWalk Therapeutics
  • Home
  • New Biology
  • Our Technology
  • Clinical Program
  • Market Potential
  • News & Events

NEW BIOLOGY DISCOVERED

About Inflammation

How can you specifically target monocytes & neutrophils?

What are Myeloid Cells?

Inflammation is your body's defense against injury and infection. Common signs of inflammation are pain, heat, redness, swelling, and loss of function. Inflammation can either happen in the short term (acute) or be a long-term response (chronic). Key cell types involved in chronic inflammation are lymphocytes (T- and B- cells), monocytes and neutrophils.

What are Myeloid Cells?

How can you specifically target monocytes & neutrophils?

What are Myeloid Cells?

Myeloid cells are a group of immune cells that form in the bone marrow and travel through the blood to inflamed tissues, where they participate in both innate and adaptive immune responses. Myeloid cells such as monocytes and neutrophils are key players in chronic inflammatory diseases.

How can you specifically target monocytes & neutrophils?

How can you specifically target monocytes & neutrophils?

How can you specifically target monocytes & neutrophils?

Our program is based on the discovery of a novel adhesion checkpoint protein called MOSPD2, which is selectively expressed on the surface of monocytes and neutrophils and controls their ability to enter inflamed tissues. 

Copyright © 2025 ImmuneWalk Therapeutics - All Rights Reserved.

Powered by

  • Contact Us

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept